ACRP CCRC EXAM PRACTICE - (130 QUESTIONS) UP-TO-DATE
ACTUAL EXAM QUESTIONS AND 100% ACCURATE SOLUTIONS |
VERIFIED ANSWERS - INSTANT PDF DOWNLOAD
Examiner/Administrator: Association of Clinical Research Professionals
CLINICAL RESEARCH
COORDINATOR CERTIFICATION
EXAMINATION
Candidate Name: _______________________________________
Candidate ID Number: ___________________________________
Testing Date: __________________________________________
Testing Center/Location: _________________________________
Signature: _____________________________________________
Candidate Instructions
• This assessment contains approximately 130 multiple-choice questions
modeled after the structure and competency areas commonly assessed in
professional clinical research coordinator certification examinations.
• Candidates are expected to demonstrate competency in informed consent,
investigational product management, regulatory compliance, ethical
principles, subject safety, protocol implementation, data integrity, and clinical
trial operations.
• Read each question carefully and select the single BEST answer. Questions
are intentionally scenario-driven and reflect complex operational and
regulatory situations encountered in clinical research settings.
• Time Allocation: 3.5 hours recommended for full examination completion.
This section contains Questions 1–30.
,• Calculators and reference materials are not permitted unless specifically
authorized by the testing administrator.
• This examination is an original educational simulation developed for
preparation purposes and is not affiliated with or copied from any official
certification examination.
Core Competency Domains
• Human Subject Protection and Research Ethics
• Informed Consent Process
• Good Clinical Practice (GCP)
• Regulatory Documentation and Compliance
• Clinical Trial Operations
• Investigational Product Accountability
• Safety Reporting and Pharmacovigilance
• Data Management and Source Documentation
• Protocol Compliance and Monitoring
• Clinical Trial Quality Management
Q1. During a multicenter Phase III oncology trial, a subject signs the informed
consent form using a legally acceptable representative because the subject is
temporarily sedated following a medical procedure. Two days later, the subject
regains decisional capacity and expresses willingness to continue participation.
What should the clinical research coordinator do NEXT?
A. Continue study participation because the legally acceptable representative
already consented
B. Obtain the subject’s direct informed consent as soon as capacity returns
C. Re-consent the subject only if new risks have been identified
D. Withdraw the subject because enrollment procedures were incomplete
Correct Answer: B. Obtain the subject’s direct informed consent as
soon as capacity returns
Explanation: When a legally authorized representative initially provides
consent because the participant lacks decision-making capacity, the subject
must personally provide informed consent once capacity is regained. This
aligns with ethical principles of autonomy and regulatory expectations under
,GCP. Option A is incorrect because proxy consent does not permanently
replace the subject’s autonomy. Option C is incorrect because re-consent is
required upon regained capacity regardless of protocol amendments. Option D
is incorrect because enrollment can continue appropriately once valid consent
is obtained directly from the participant.
Q2. A sponsor issues a protocol amendment adding additional laboratory
assessments that increase participant burden but do not significantly alter study
risk. Before implementing the amendment at the site, the coordinator must
FIRST ensure:
A. Immediate implementation to avoid protocol deviations
B. Approval from the Institutional Review Board/Ethics Committee unless
immediate hazards exist
C. Sponsor monitoring visit completion
D. Subject notification after implementation
Correct Answer: B. Approval from the Institutional Review
Board/Ethics Committee unless immediate hazards exist
Explanation: Protocol amendments affecting participant procedures require
IRB/IEC approval before implementation unless necessary to eliminate
immediate hazards to participants. Option A violates regulatory procedures.
Option C is unrelated to authorization requirements. Option D is insufficient
because ethical oversight approval must precede implementation.
Q3. During source data review, a monitor discovers that a coordinator corrected
a laboratory value by using correction fluid and overwriting the original entry.
Which GCP principle has MOST likely been violated?
A. Subject confidentiality
B. Investigator delegation
C. ALCOA documentation standards
D. Sponsor oversight obligations
Correct Answer: C. ALCOA documentation standards
Explanation: ALCOA principles require data to be attributable, legible,
contemporaneous, original, and accurate. Using correction fluid obscures the
original data and compromises auditability. Option A concerns privacy
, protections rather than data integrity. Option B relates to task delegation.
Option D concerns sponsor responsibilities but does not specifically address
improper documentation practices.
Q4. A subject enrolled in a cardiovascular device trial reports chest pain
requiring emergency hospitalization. The investigator determines the event is
unexpected and possibly related to the investigational device. The coordinator
should ensure the event is reported:
A. Only during the next scheduled monitoring visit
B. According to sponsor and regulatory reporting timelines for serious adverse
events
C. Only if the subject withdraws from the study
D. After all diagnostic testing has been completed
Correct Answer: B. According to sponsor and regulatory reporting
timelines for serious adverse events
Explanation: Serious adverse events that are unexpected and potentially
related require prompt reporting according to sponsor, IRB, and regulatory
timelines. Option A delays mandatory reporting. Option C incorrectly ties
reporting to withdrawal status. Option D may dangerously delay required
notification.
Q5. Which document BEST demonstrates that site personnel are qualified to
perform delegated clinical trial tasks?
A. Financial disclosure form
B. Subject screening log
C. Delegation of authority log with supporting qualifications
D. Monitoring visit follow-up letter
Correct Answer: C. Delegation of authority log with supporting
qualifications
Explanation: Delegation logs identify assigned responsibilities and verify
personnel qualifications and authorization. Supporting documents such as CVs
and licenses further demonstrate competency. Option A addresses conflict-of-
interest disclosure. Option B tracks recruitment activity. Option D summarizes
monitoring findings rather than delegation authority.
ACTUAL EXAM QUESTIONS AND 100% ACCURATE SOLUTIONS |
VERIFIED ANSWERS - INSTANT PDF DOWNLOAD
Examiner/Administrator: Association of Clinical Research Professionals
CLINICAL RESEARCH
COORDINATOR CERTIFICATION
EXAMINATION
Candidate Name: _______________________________________
Candidate ID Number: ___________________________________
Testing Date: __________________________________________
Testing Center/Location: _________________________________
Signature: _____________________________________________
Candidate Instructions
• This assessment contains approximately 130 multiple-choice questions
modeled after the structure and competency areas commonly assessed in
professional clinical research coordinator certification examinations.
• Candidates are expected to demonstrate competency in informed consent,
investigational product management, regulatory compliance, ethical
principles, subject safety, protocol implementation, data integrity, and clinical
trial operations.
• Read each question carefully and select the single BEST answer. Questions
are intentionally scenario-driven and reflect complex operational and
regulatory situations encountered in clinical research settings.
• Time Allocation: 3.5 hours recommended for full examination completion.
This section contains Questions 1–30.
,• Calculators and reference materials are not permitted unless specifically
authorized by the testing administrator.
• This examination is an original educational simulation developed for
preparation purposes and is not affiliated with or copied from any official
certification examination.
Core Competency Domains
• Human Subject Protection and Research Ethics
• Informed Consent Process
• Good Clinical Practice (GCP)
• Regulatory Documentation and Compliance
• Clinical Trial Operations
• Investigational Product Accountability
• Safety Reporting and Pharmacovigilance
• Data Management and Source Documentation
• Protocol Compliance and Monitoring
• Clinical Trial Quality Management
Q1. During a multicenter Phase III oncology trial, a subject signs the informed
consent form using a legally acceptable representative because the subject is
temporarily sedated following a medical procedure. Two days later, the subject
regains decisional capacity and expresses willingness to continue participation.
What should the clinical research coordinator do NEXT?
A. Continue study participation because the legally acceptable representative
already consented
B. Obtain the subject’s direct informed consent as soon as capacity returns
C. Re-consent the subject only if new risks have been identified
D. Withdraw the subject because enrollment procedures were incomplete
Correct Answer: B. Obtain the subject’s direct informed consent as
soon as capacity returns
Explanation: When a legally authorized representative initially provides
consent because the participant lacks decision-making capacity, the subject
must personally provide informed consent once capacity is regained. This
aligns with ethical principles of autonomy and regulatory expectations under
,GCP. Option A is incorrect because proxy consent does not permanently
replace the subject’s autonomy. Option C is incorrect because re-consent is
required upon regained capacity regardless of protocol amendments. Option D
is incorrect because enrollment can continue appropriately once valid consent
is obtained directly from the participant.
Q2. A sponsor issues a protocol amendment adding additional laboratory
assessments that increase participant burden but do not significantly alter study
risk. Before implementing the amendment at the site, the coordinator must
FIRST ensure:
A. Immediate implementation to avoid protocol deviations
B. Approval from the Institutional Review Board/Ethics Committee unless
immediate hazards exist
C. Sponsor monitoring visit completion
D. Subject notification after implementation
Correct Answer: B. Approval from the Institutional Review
Board/Ethics Committee unless immediate hazards exist
Explanation: Protocol amendments affecting participant procedures require
IRB/IEC approval before implementation unless necessary to eliminate
immediate hazards to participants. Option A violates regulatory procedures.
Option C is unrelated to authorization requirements. Option D is insufficient
because ethical oversight approval must precede implementation.
Q3. During source data review, a monitor discovers that a coordinator corrected
a laboratory value by using correction fluid and overwriting the original entry.
Which GCP principle has MOST likely been violated?
A. Subject confidentiality
B. Investigator delegation
C. ALCOA documentation standards
D. Sponsor oversight obligations
Correct Answer: C. ALCOA documentation standards
Explanation: ALCOA principles require data to be attributable, legible,
contemporaneous, original, and accurate. Using correction fluid obscures the
original data and compromises auditability. Option A concerns privacy
, protections rather than data integrity. Option B relates to task delegation.
Option D concerns sponsor responsibilities but does not specifically address
improper documentation practices.
Q4. A subject enrolled in a cardiovascular device trial reports chest pain
requiring emergency hospitalization. The investigator determines the event is
unexpected and possibly related to the investigational device. The coordinator
should ensure the event is reported:
A. Only during the next scheduled monitoring visit
B. According to sponsor and regulatory reporting timelines for serious adverse
events
C. Only if the subject withdraws from the study
D. After all diagnostic testing has been completed
Correct Answer: B. According to sponsor and regulatory reporting
timelines for serious adverse events
Explanation: Serious adverse events that are unexpected and potentially
related require prompt reporting according to sponsor, IRB, and regulatory
timelines. Option A delays mandatory reporting. Option C incorrectly ties
reporting to withdrawal status. Option D may dangerously delay required
notification.
Q5. Which document BEST demonstrates that site personnel are qualified to
perform delegated clinical trial tasks?
A. Financial disclosure form
B. Subject screening log
C. Delegation of authority log with supporting qualifications
D. Monitoring visit follow-up letter
Correct Answer: C. Delegation of authority log with supporting
qualifications
Explanation: Delegation logs identify assigned responsibilities and verify
personnel qualifications and authorization. Supporting documents such as CVs
and licenses further demonstrate competency. Option A addresses conflict-of-
interest disclosure. Option B tracks recruitment activity. Option D summarizes
monitoring findings rather than delegation authority.
